- RecruitingPhase II
A study to explore the effect of immunotherapy drug, tebentafusp, on patients with clear cell sarcoma (ultra-rare, aggressive type of soft tissue sarcoma that primarily affects young adults)
This study looks at a medicine called tebentafusp for a rare cancer called clear cell sarcoma. Researchers want to see if the drug works and how long its effects last. It's for adults with advanced clear cell sarcoma.
For: Clear cell sarcomaUnited Kingdom · England - RecruitingPHASE3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
This study looks at a new drug, tebentafusp, for people with advanced melanoma that has already been treated. We want to see if tebentafusp, alone or with another drug called pembrolizumab, works better and is safer than standard treatments or best supportive care.
For: Advanced MelanomaUnited States · Australia · Austria - Active not recruitingPHASE2
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
This study looks at using a new blood test to help decide when to give a drug called tebentafusp to people with certain types of melanoma that have been treated but could come back. The aim is to see if tebentafusp can help them live longer.
For: Melanoma (Skin) · Melanoma, UvealUnited Kingdom - RecruitingPHASE3
Adjuvant Tebentafusp in High Risk Ocular Melanoma
This study is testing a new medicine, tebentafusp, for people with a type of eye cancer called uveal melanoma. The aim is to see if it can stop the cancer from coming back after initial treatment, especially for those at high risk.
For: Uveal MelanomaUnited States · Belgium · France - RecruitingPHASE2
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This study is testing a new drug called tebentafusp for advanced clear cell sarcoma. It's for patients whose cancer cells have a specific marker called HLA-A*02:01. We want to see if the drug can help shrink the tumour or stop it from growing.
For: HLA-A*0201 Positive Cells Present · Clear Cell Sarcoma (CCS)United States · United Kingdom